Abstract
This chapter critically explores the extent to which pharmaceutical companies have a moral obligation to assist poor patients in least developed countries (LDCs) who currently have no or inadequate access to lifesaving medications. Focusing on the ongoing HIV/AIDS epidemic in LDCs, the first section of this essay begins with some background information of the disproportionate burden of HIV/AIDS in LDCs. The second section provides a brief overview of some of the salient arguments for holding multinational antiretroviral treatment (ART) manufacturers as morally responsible for easing the disproportionate global disease burden. The third section explains that these arguments regarding pharmaceutical companies’ duty to assist are going too far on the one hand by downplaying other non-pharmacological contributors to the slow response, but are also not going far enough on the other hand in upholding reciprocity-based duties. As the international community and researchers battle the reemergence of Ebola in Africa, the fourth section explores how lessons from the HIV/AIDS situation can help to address what pharmaceutical companies may subsequently owe patients in this region and how the international community should respond to ongoing unequal disease burden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Access to Medicine Index. 2014. Licensing Medicines for HIV/AIDS: Critical Mechanism for Ending the Epidemic. http://www.accesstomedicineindex.org/licensing-medicines-hivaids-critical-mechanism-ending-epidemic. Accessed 18 Feb 2015.
Angell, M. 2004. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.
Badcott, D. 2013. Big Pharma: A Former Insider’s View. Medicine, Health Care and Philosophy 16: 249–264.
Bill & Melinda Gates Foundation. 2015. www.gatesfoundation.org. Accessed 18 Feb 2015.
Chang, P.L. 2006. Who’s in the Business of Saving Lives? The Journal of Medicine and Philosophy 31(5): 465–482.
Clinton Health Access Initiative. Dec 2014. ARV Market Report: The State of the Antiretroviral Drug Market in Low- and Middle-income Countries. Boston: USA.
Cohen, M.S., et al. 2011. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. The New England Journal of Medicine 365(5): 493–505.
De George, R.T. 2005a. Intellectual Property and Pharmaceutical Drugs: An Ethical Analysis. Business Ethics Quarterly 15(4): 549–575.
———. 2005b. Business Ethics. 6th ed. Upper Saddle River: Prentice Hall.
Donovan, G. 2014. Ebola, Epidemics, and Ethics—What We Have Learned. Philosophy, Ethics, and Humanities in Medicine 9: 15.
Finegold, D., and A. Moser. 2006. Ethical Decision-making in Bioscience Firms. Nature Biotechnology 24(3): 285–290.
Goodin, R. 1985. Protecting the Vulnerable: A Reanalysis of Our Social Responsibilities. Chicago: University of Chicago Press.
Gruskin, S., and Z. Raad. 2010. Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment. PLoS Medicine 7(9): 1–3.
Hanson, K., et al. 2003. Expanding Access to Priority Health Interventions: A Framework for Understanding the Constraints to Scaling-Up. Journal of International Development 15: 1–14.
Ho, A. 2005. Pharmaceutical Corporations and the Duty to Aid in HIV/AIDS Epidemic. Business & Professional Ethics Journal 24(4): 51–81.
Holm, S. 2000. Three Reasons Why a Global Market in Pharmaceutical Products Is Inherently Unjust. Journal of Social Philosophy 31: 398.
Huebner, J.M. 2014. Moral Psychology and the Intuition that Pharmaceutical Companies Have a ‘Special’ Obligation to Society. Journal of Business Ethics 122: 501–510.
Jackson, K. 1993. Global Distributive Justice and the Corporate Duty to Aid. Journal of Business Ethics 12: 549.
Joffe, S. 2014. Evaluating Novel Therapies During the Ebola Epidemic. Journal of the American Medical Association 312(13): 1299–1300.
Kelly, M. 2001. Property Privileges (Not Rights): The Cipro case reminds us that property rights are subordinate to the public good. Business Ethics 15(6, Nov/Dec): 4.
Kroll, D. 2014. Ebola ‘Secret Serum’: Small Biopharma, The Army and Big Tobacco. Forbes. http://www.forbes.com/sites/davidkroll/2014/08/05/ebola-secret-serum-small-biopharma-the-army-and-big-tobacco/. Accessed 23 Feb 2015.
Leisinger, K.M. 2005. The Corporate Social Responsibility of the Pharmaceutical Industry: Idealism Without Illusion and Realism Without Resignation. Business Ethics Quarterly 15(4): 577–594.
Leventer, H. 2002. It Is Not Unethical, Though It Is Often Unwise, to Override Patents. The American Journal of Bioethics 2: 50.
McGraw, A.P., J.A. Schwartz, and P.E. Tetlock. 2011. From the Commercial to the Communal: Reframing Taboo Trade-offs in Religious and Pharmaceutical Marketing. Journal of Consumer Research 39: 157–173.
Medicine Patent Pool. 2015. About the MPP. http://www.medicinespatentpool.org/about/. Accessed 18 Feb 2015.
Miller, C.L., et al. 2011. Food Insecurity and Sexual Risk in an HIV Endemic Community in Uganda. AIDS and Behavior 15(7): 1512–1519.
National Institute of Allergy and Infectious Diseases (NIAID). 2015. Ebola Vaccine Trial Opens in Liberia—Study Led by Liberia-NIH Partnership Will Test Two Experimental Vaccines. http://www.niaid.nih.gov/news/newsreleases/2015/Pages/PREVAIL.aspx. Accessed 1 Mar 2015.
Nunn, A., E. Fonseca, and S. Gruskin. 2009. Changing Global Essential Medicines Norms to Improve Access to AIDS Treatment: Lessons from Brazil. Global Public Health 4(2): 131–149.
Onishi, N. 2015, April 11. Empty Ebola Clinics in Liberia are Seen as Misstep in U.S. Relief Effort. New York Times. http://www.nytimes.com/2015/04/12/world/africa/idle-ebola-clinics-in-liberia-are-seen-as-misstep-in-us-relief-effort.html. Accessed 16 Apr 2015.
Pogge, T.W. 2005. World Poverty and Human Rights. Ethics International Affairs 19: 4.
Pollack, A. 2014, August 8. Ebola Drug Could Save a Few Lives. But Whose? New York Times. http://www.nytimes.com/2014/08/09/health/in-ebola-outbreak-who-should-get-experimental-drug.html. Accessed 4 Mar 2015.
Population Reference Bureau. 2014 Africa—Sub-Saharan. http://www.prb.org/DataFinder/Geography/Data.aspx?loc=247. Accessed 18 Feb 2015.
Reich, M. 1993. Essential Drugs: Economics and Politics in International Health. In The Pharmaceutical Corporate Presence in Developing Countries, ed. Travis and Williams, 83–108. Notre Dame, Indiana: University of Notre Dame Press.
Resnik, D.B. 2001. Developing Drugs for the Developing World: An Economic, Legal, Moral, and Political Dilemma. Developing World Bioethics 1(1): 11–32.
Rettner, R. 2014. Could Ebola Really Be The ‘Next AIDS’? Lifescience. http://www.livescience.com/48232-ebola-aids-comparison.html. Accessed 23 Feb 2015.
Rid, A., and E.J. Emanuel. 2014. Ethical Considerations of Experimental Interventions in the Ebola Outbreak. Lancet 384(9957): 1896–1899.
Sayburn, A. 2014. WHO Gives Go Ahead for Experimental Treatments to be Used in Ebola Outbreak. British Medical Journal 349: g5161.
Scanlon, T.M. 1998. What We Owe to Each Other. Cambridge, MA: Belknap Press of Harvard University Press.
Schneider, H., et al. 2006. Health Systems and Access to Antiretroviral Drugs for HIV in Southern Africa: Service Delivery and Human Resource Challenges. Reproductive Health Matters 14(27): 12–23.
Schüklenk, U., and R.E. Ashcroft. 2002. Affordable Access to Essential Medication in Developing Countries: Conflicts Between Ethical and Economic Imperatives. The Journal of Medicine and Philosophy 27(2): 179–195.
Setayesh, H., et al. 2014. HIV and AIDS in the Middle East and North Africa. Washington, DC: Population Reference Bureau.
Singer, P. 1972. Famine, Affluence, and Morality. Philosophy and Public Affairs 1: 229–243.
Spinello, R.A. 1992. Ethics, Pricing and the Pharmaceutical Industry. Journal of Business Ethics 11(8): 617–626.
Streckx, S. 2004. Patents and Access to Drugs in Developing Countries: An Ethical Analysis. Developing World Bioethics 4(1): 1471–8847.
The Global Fund to Fight AIDS, Tuberculosis and Malaria. n.d. http://www.theglobalfund.org/en/. Accessed 18 Feb 2015.
The World Bank. 2014. Worldwide Governance Reports: Country Data Reports. http://info.worldbank.org/governance/wgi/index.aspx#countryReports. Accessed 27 Feb 2015.
———. 2015a. Military expenditure (% of GDP). http://data.worldbank.org/indicator/MS.MIL.XPND.GD.ZS/countries. Accessed 27 Feb 2015.
———. 2015b Health expenditure, total (% of GDP). http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS/countries. Accessed 27 Feb 2015.
Thigpen, M.C., et al. 2012. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. The New England Journal of Medicine 367: 423–434.
Tsai, A.C., D.R. Bangsberg, and S.D. Weiser. 2013. Harnessing Poverty Alleviation to Reduce the Stigma of HIV in Sub-Saharan Africa. PLoS Medicine 10(11): e1001557.
UNAIDS. 2010. Removing Bottle-necks for Universal Access in Central African Republic. http://www.unaids.org/en/resources/presscentre/featurestories/2010/february/20100208car. Accessed 23 Feb 2015.
———. 2014a. Fact sheet. http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet. Accessed 18 Feb 2015.
———. 2014b. The Gap Report. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf. Accessed 18 Feb 2015.
———. 2014c. UNAIDS Report Shows that 19 Million of the 35 Million People Living with HIV Today Do Not Know that They Have the Virus. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/july/20140716prgapreport. Accessed 18 Feb 2015.
———. 2014d. Raising Awareness of HIV Testing and Counselling in South Sudan. http://www.unaids.org/en/resources/presscentre/featurestories/2014/june/20140623southsudantesting. Accessed 23 Feb 2015.
United Nations. Declaration of Universal Human Rights. http://www.un.org/Overview/rights.html. Accessed 18 Feb 2015.
United Nations Development Programme. 2013. Human Development Report 2013. The Rise of the South: Human Progress in a Diverse World. http://hdr.undp.org/sites/default/files/reports/14/hdr2013_en_complete.pdf. Accessed 18 Feb 2015.
Wettstein, F. 2012. CSR and the Debate on Business and Human Rights: Bridging the Great Divide. Business Ethics Quarterly 22(4): 739–770.
World Health Organization. 2006. Constitution of the World Health Organization. http://www.who.int/governance/eb/who_constitution_en.pdf. Accessed 18 Feb 2015.
———. 2011. Global Health Sector Strategy on HIV/AIDS 2011–2015. http://whqlibdoc.who.int/publications/2011/9789241501651_eng.pdf?ua=1. Accessed 23 Feb 2015.
———. 2014. Fact Sheet No. 104 Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 18 Feb 2015.
———. 2015a Essential Medicines and Health Products. http://www.who.int/medicines/services/essmedicines_def/en/. Accessed 18 Feb 2015.
———. 2015b Health Workforce: Density of Physicians (Total Number per 1000 Population): Latest available year. http://gamapserver.who.int/gho/interactive_charts/health_workforce/PhysiciansDensity_Total/tablet/atlas.html. Accessed 27 Feb 2015.
———. 2015c. Ebola Situation Report–8 April 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-8-april-2015. Accessed 16 April 2015.
Youde, J. 2005. The Development of a Counter-Epistemic Community: AIDS, South Africa, and International Regimes. International Relations 19: 421–439.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ho, A. (2017). Global Health Disparity and Pharmaceutical Companies’ Obligation to Assist. In: Ho, D. (eds) Philosophical Issues in Pharmaceutics. Philosophy and Medicine, vol 122. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-0979-6_3
Download citation
DOI: https://doi.org/10.1007/978-94-024-0979-6_3
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-0977-2
Online ISBN: 978-94-024-0979-6
eBook Packages: Religion and PhilosophyPhilosophy and Religion (R0)